Search review questions

Proportion of participants who required further glaucoma surgeryat 24 months (medium‐term) · people with open‐angle glaucoma

Mean change in health‐related quality of life · people with open‐angle glaucoma

Rate of visual field progression or proportion of participants whose field loss progressed · people with open‐angle glaucoma

Proportion of participants experiencing postoperative complicationsover 24 months (medium‐term) · people with open‐angle glaucoma

Mean pupillary diameter—at the time the surgeon performs capsulorhexis (mm) · patients undergoing cataract surgery

AE: cystoid macular edema · patients undergoing cataract surgery

AE: cystoid macular edema ‐ any time point during or after surgery · patients undergoing cataract surgery

Mean pupillary diameter—at the time the surgeon performs capsulorhexis (mm) · patients undergoing cataract surgery

Mean pupillary diameter—at the beginning of cataract surgery (mm) · patients undergoing cataract surgery

Mean pupillary diameter—at the end of cataract surgery (mm) · patients undergoing cataract surgery

Intraoperative surgical time—total intraoperative time (min) · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—week 1 · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—month 1 · patients undergoing cataract surgery

AE: vitreous loss—any time point during or after surgery · patients undergoing cataract surgery

Mean pupillary diameter—at the time the surgeon performs capsulorhexis (mm) · patients undergoing cataract surgery

Mean pupillary diameter—at the beginning of cataract surgery (mm) · patients undergoing cataract surgery

Mean pupillary diameter—at the beginning of cataract surgery (mm) · patients undergoing cataract surgery

Mean pupillary diameter—at the end of cataract surgery (mm) · patients undergoing cataract surgery

Intraoperative surgical time—total intraoperative time (min) · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—week 1 · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—month 1 · patients undergoing cataract surgery

Adverse events · patients undergoing cataract surgery

Mean pupillary diameter—at the end of cataract surgery (mm) · patients undergoing cataract surgery

Total intraoperative surgical time (min) · patients undergoing cataract surgery

Total time it took for the surgeon to perform phacoemulsification (seconds) · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—week 1 · patients undergoing cataract surgery

AE: participant‐reported ocular discomfort—month 1 · patients undergoing cataract surgery

AE: posterior capsule rupture · patients undergoing cataract surgery

AE: posterior capsule rupture—any time point during or after surgery · patients undergoing cataract surgery

Best‐corrected visual acuity at 12 months [logMAR] Measured on the logMAR scale, range ‐1.3 to 1.0. Lower scores represent better vision. · people with non‐exudative AMD (AREDS 2 to 4)

Contrast sensitivity at Level E [18 cycles/degree] at 12 months Higher scores represent better contrast sensitivity. · people with non‐exudative AMD (AREDS 2 to 4)

Near vision · people with non‐exudative AMD (AREDS 2 to 4)

Low luminance deficit score · people with non‐exudative AMD (AREDS 2 to 4)

Reading speed · people with non‐exudative AMD (AREDS 2 to 4)

Self‐reported visual function at 12 months · people with non‐exudative AMD (AREDS 2 to 4)

Adverse events: AMD progression at 12 months Defined as increased drusen volume or onset of advanced AMD. Conversion to exudative AMD at 12 months Assessed by clinical examination and retinal optical coherence tomography. · people with non‐exudative AMD (AREDS 2 to 4)

Mean change in VA · people with epiretinal membrane

Proportion of eyes with gain in VA by 0.3 logMAR or greater · people with epiretinal membrane

Proportion of eyes with loss in VA by 0.3 logMAR or greater · people with epiretinal membrane

Quality of life · people with epiretinal membrane

Adverse effects · people with epiretinal membrane

Change in binocular best‐corrected distance visual acuity · infantile nystagmus syndrome

Change in head posture ‐ not reported · infantile nystagmus syndrome

Change in intensity of the nystagmus waveform · infantile nystagmus syndrome

Change in foveation period durations of the waveform ‐ not reported · infantile nystagmus syndrome

Change in visual recognition times ‐ not reported · infantile nystagmus syndrome

Change in proportion of participants with adverse effects with a probable causal link to the treatment · infantile nystagmus syndrome

Change in quality of life · infantile nystagmus syndrome

Mean change in maximum K from baseline or final value—at 12 months or more (diopters) · participants with keratoconus

Proportion of participants whose maximum K decreased by at least 2 diopters—at 24 months · participants with progressive keratoconus